Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

advanced breast cancer, particularly for patients with HER2-negative breast cancer and triple-negative breast cancer." 

Positive Phase 2 data for NKTR-102 were recently published in Lancet Oncology in November 2013. (1)  Etirinotecan pegol achieved a confirmed objective response rate by RECIST of 29 percent. NKTR-102 demonstrated a high clinical benefit rate (CR+PR+SD greater than six months) of 37 percent (13/35) in the 14-day group and 49 percent (17/35) in the 21-day group. Six patients experienced 100 percent resolution of all target lesions, with two complete RECIST responses and four near-complete responses.
Patients treated exhibited low rates of alopecia, neuropathy and neutropenia, which are significant adverse events associated with existing breast cancer therapies. Side effects were generally manageable; the most common Grade 3 toxicity was diarrhea (17-23%) typically occurring after three months of therapy.

About the BEACON StudyBEACON is a Phase 3, open-label, randomized, multicenter study of NKTR-102 which enrolled 852 women with locally recurrent or metastatic breast cancer, who have previously been treated with ATC. The trial is being conducted at approximately 150 sites worldwide including North America, Western Europe, Russia and the Republic of Korea.  Nearly half of the patients enrolled in BEACON were located in North America.  Patients were randomized on a 1:1 basis to receive 145 mg/m2 of single-agent NKTR-102 once every three weeks or a single agent of physician's choice.  The physician's choice agents include: ixabepilone, vinorelbine, gemcitabine, eribulin, or a taxane.  Randomization was stratified by geographic region, prior use of eribulin and receptor status. 

The primary endpoint of the BEACON study is overall survival; secondary endpoints include progression-free survival, objective tumor response
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
(Date:9/2/2014)... 2, 2014    - ... muestran agentes antitrombóticos no utilizados óptimamente para prevenir ... Las presentaciones de GARFIELD-AF en el ESC CONGRESS ... los resultados de pacientes en riesgo de sufrir ... Los datos de casi 12.500 pacientes ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... -- Complications are rare among breast cancer patients ... indicates. However, the researchers did find that ... higher risk for certain complications than a single ... breast cancer patients who had a single (64 ... and were followed for 30 days after surgery. ...
(Date:9/2/2014)... their own spread throughout the body by coaxing cells ... to a new report by Johns Hopkins scientists. , ... Communications , the researchers describe animal and cell-culture experiments ... by breast cancer cells. These molecules cause lymphatic endothelial ... produce proteins called CCL5 and VEGF. CCL5 attracts tumor ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Operators in ... to millions of people annually, arranging care and counsel ... and private enterprises are expected to derive $39.4 billion ... donations and private income. Over the five years through ... annualised rate of 6.6%, including growth of 4.1% in ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Melatonin supplements did not ... fractures, a new study found. Many older hospital ... due to disruption of their normal sleep-wake cycle. A ... that contributes to delirium, but there has been little ... This study included 378 patients, average age 84, ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... screening program to detect peripheral arterial disease (PAD) on time ... For Life? this program can help detect the onset of ... of having an amputation by half. // ... affects every vascular bed in the body and it increases ...
... has the remarkable ability to discriminate between self and ... immune system, the human body would have lost its ... // ,The immune system produces certain substances ... cells, effectively labeling them as "bad" so that other ...
... Baptist Medical Center certain herbs and dietary supplements can ... other gastrointestinal problems.// ,The researcher Kemper, had ... were out there doing, and came up with a ... historically, 50 years ago, people used home remedies. Then ...
... unusual antibiotics that have the potential to be effective ... at the 230th national meeting of the American Chemical ... ,The new antibiotics are synthetic forms of cephalosporin, a ... kill bacteria by masquerading as components of the bacterial ...
... a research team led by the National Human Genome ... experimental anti-cancer drugs also shows promise in laboratory studies ... aging. // ,These drugs belong to a ... tested in people with myeloid leukemia, neurofibromatosis and other ...
... loss of interest in eating during old age is the ... a plan which will help older people eat nutritious food ... ,Doctors at the institute advise that High fibre in ... can help fight diabetes, heart disease and diverticulosis. Folic acid ...
Cached Medicine News:Health News:Diabetic Amputation May Reduce If Free Screenings Are There 2Health News:Fighting against disease as easy as eating eggs 2Health News:Atypical Antibiotics For Super Bugs 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: